TOMI Environmental Solutions (TOMZ) Q4 2025 earnings review
Backlog Hits Record High, But Severe Liquidity Crunch Overshadows Growth
TOMI ended FY25 with a precarious dichotomy: an expanding pipeline and a critical cash shortage. While full-year revenue contracted 27% to $5.64M, management highlighted a record $1.8M backlog and an integration pipeline of $16M. However, capital expenditure deferrals severely impacted the top line, with Q4 sales decelerating to an implied $1.02M. More alarmingly, the company exited the year with just $88k in cash, forcing reliance on a new $20M Equity Line of Credit (ELOC). Hidden beneath the full-year 55% gross margin figure is an implied Q4 margin collapse to just 21%.
🐂 Bull Case
The sales backlog doubled year-over-year to $1.8M, representing improved near-term revenue visibility. Total opportunity books for integration projects and SteraMist iHP stand at $16M and $20M, respectively.
International sales grew to 29% of total revenue in 2025 (up from 21% in 2024), driven by market penetration in Canada, the UK, and Europe, including a strategic partnership with Total Clean Air.
🐻 Bear Case
Ending the year with a mere $88,000 in cash limits operational flexibility. The company will have to rely heavily on its $20M ELOC, exposing shareholders to massive dilution risk.
While management highlighted a healthy 55% gross margin for the full year, backing out Q1-Q3 results reveals that Q4 gross margins collapsed to an implied 21% on $1.02M in revenue.
⚖️ Verdict: 🔴
Bearish. The expanding backlog and new OEM partnerships are positive, but the financial foundation is currently too weak. Persistent CapEx deferrals, a deteriorating gross margin in Q4, and the inevitable dilution from emergency equity taps outweigh the operational narrative.
Key Themes
Liquidity Crisis and Dilution Risk
Cash and equivalents deteriorated aggressively throughout the year, dropping from $665K at the end of 2024 to just $88K by December 31, 2025. With a full-year operating cash burn of $1.2M, TOMI is now entirely dependent on its $20M ELOC (with a first draw of $94K already made in Feb 2026) and a $50M shelf registration. This structural cash deficit guarantees imminent and likely substantial shareholder dilution.
Hidden Q4 Gross Margin Compression
Management touted a 'healthy' full-year gross margin of 55%. However, calculating implied Q4 results (subtracting nine-month YTD figures from FY25 totals) exposes a significant operational red flag. Q4 generated just $216K in gross profit on $1.02M of revenue—an implied margin of roughly 21%. This is a severe deceleration from the ~60% margins achieved consistently through Q1-Q3 and requires management explanation.
Custom Integration (CES/SIS) Pipeline Conversion
A key growth engine is the Custom Engineered System (CES) and SteraMist Integration System (SIS). The company confirmed ten active integration projects with a combined contract value of ~$3M, including a $500K signed PO from a global biopharma leader. Strategic OEM partnerships with ESCO, Steelco, PBSC, Nuaire, and Getinge are vital for embedding TOMI's technology directly into manufacturing hardware.
Persistent CapEx Deferrals Linked to Macro Environment
Full-year revenue declined 27% to $5.64M, which management attributed entirely to customers deferring capital expenditure projects. Cited culprits include tariff impacts, economic uncertainty, and the Middle East crisis. While management views this as a 'temporary timing issue,' this narrative has persisted since Q2, indicating that sales cycles for capital equipment have structurally lengthened.
Expanding Regulatory and Target Verticals
Beyond traditional life sciences, the company is seeing regulatory tailwinds open new multi-million dollar verticals. The $31M food safety market is being unlocked via recent FDA developments, allowing SteraMist applications in processing environments. Additionally, an EPA push for biofuels and a USDA study confirming BIT efficacy against honeybee deformed wing virus present novel environmental biosecurity revenue streams.
Other KPIs
Accelerating. The backlog doubled from $0.88M at the end of 2024 to $1.8M by December 31, 2025. This metric is the strongest indicator that demand remains intact despite the delayed revenue recognition in current periods.
Decelerating. Total operating expenses were reduced by approximately 10% YoY (down from $7.66M in 2024). SG&A specifically dropped from $5.12M to $4.53M, reflecting disciplined cost management, though this wasn't enough to offset the severe drop in top-line revenue.
Total debt increased from $2.36M at the end of 2024, primarily due to a new $535K convertible note financing completed during the year to fund operations. Management is evaluating options to convert this debt into equity to clean up the balance sheet, which would cause additional dilution.
Guidance
Accelerating. Management explicitly stated that they are 'beating first quarter 2025 revenue' as they close out Q1 2026. Given that 25Q1 revenue was $1.57M, this implies sequential acceleration from the implied $1.02M generated in 25Q4.
Key Questions
Q4 Margin Compression
Gross margins averaged over 60% for the first nine months of the year, yet implied Q4 results suggest a gross margin of just 21%. Were there significant one-time inventory write-downs or pricing concessions at year-end that caused this collapse?
Liquidity Strategy
With only $88,000 in cash at year-end, what is the anticipated cash burn rate for 2026, and exactly how much do you plan to draw from the Hudson Global ELOC over the next two quarters?
CapEx Deferrals
You attributed the $2.1M YoY revenue drop to macroeconomic-driven CapEx deferrals. Of the projects delayed in 2025, what percentage has been firmly rescheduled with signed POs for 2026 versus indefinitely stalled?